Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 6/20 | 0.37 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.35 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.31 |
| ▸ | PRKDC | P78527 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31723867 | 1.00 | TDP1 (0.38) | TDP1ERN1TRIM24TRIM33LMNA | |
| SCHEMBL16333251 | 0.83 | TDP1 (0.42) | TDP1ERN1TRIM24TRIM33LMNA | |
| SCHEMBL19794988 | 0.78 | LMNA (0.41) | ERN1TRIM24TRIM33LMNAALDH1A1 | |
| SCHEMBL29411231 | 0.78 | LMNA (0.41) | ERN1TRIM24TRIM33LMNAALDH1A1 | |
| SCHEMBL1533918 | 0.78 | TDP1 (0.40) | TDP1ERN1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL30589401 | 0.78 | TDP1 (0.40) | TDP1ERN1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL2213250 | 0.75 | ERN1 (0.35) | ERN1TRIM24TRIM33LMNAPRKDC | |
| SCHEMBL15012943 | 0.75 | TDP1 (0.38) | TDP1ERN1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL22466186 | 0.75 | ERN1 (0.48) | ERN1TRIM24TRIM33 | |
| SCHEMBL29964486 | 0.75 | ERN1 (0.35) | ERN1TRIM24TRIM33LMNAPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791100-B2 | Aryl benzylamine compounds | NOVARTIS AG (CH) | 2014-07-29 | — | — | US | disclosed |
| EP-2531487-B1 | ARYL BENZYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2014-06-18 | — | — | EP | disclosed |
| EP-2531487-A1 | ARYL BENZYLAMINE COMPOUNDS | Novartis AG (CH) | 2012-12-12 | — | — | EP | disclosed |
| CN-102741227-A | Aryl benzylamine compounds | NOVARTIS AG | 2012-10-17 | — | — | CN | disclosed |
| US-20120046293-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2012-02-23 | — | — | US | disclosed |
| US-8063105-B2 | Renin inhibitors | MERCK CANADA INC. (CA) | 2011-11-22 | — | — | US | disclosed |
| WO-2011095452-A1 | ARYL BENZYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2011-08-11 | — | — | WO | disclosed |
| US-20110190258-A1 | ARYL BENZYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2011-08-04 | — | — | US | disclosed |
| US-7968720-B2 | Secondary amines as renin inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-06-28 | — | — | US | disclosed |
| US-20090281103-A1 | Renin Inhibitors | MERCK CANADA INC. (CA) | 2009-11-12 | — | — | US | disclosed |
| CN-101395135-A | Novel primary amides | ACTELION PHARMACEUTICALS LTD (CH) | 2009-03-25 | — | — | CN | disclosed |
| US-20090062342-A1 | AMINES | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-03-05 | — | — | US | disclosed |
| EP-2029542-A2 | PRIMARY AMINES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2009-03-04 | — | — | EP | disclosed |
| EP-1994026-A2 | NEW AMINES | Actelion Pharmaceuticals Ltd. (CH) | 2008-11-26 | — | — | EP | disclosed |
| EP-1981847-A1 | SECONDARY AMINES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2008-10-22 | — | — | EP | disclosed |
| EP-1910272-A1 | RENIN INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007102127-A2 | NEW AMINES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007099509-A2 | PRIMARY AMINES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007088514-A1 | SECONDARY AMINES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007009250-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046293-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | TDP1 3552/4885ERN1 1487/4885TRIM24 3856/4885 |
| US-20090281103-A1 | Renin Inhibitors | REN, ACE, AGT | TDP1 3674/4885ERN1 1463/4885TRIM24 3917/4885 |
| US-20090062342-A1 | AMINES | REN, ACE, MAOA | TDP1 2258/4885ERN1 2636/4885TRIM24 4445/4885 |
| US-20110190258-A1 | ARYL BENZYLAMINE COMPOUNDS | UGT2B7, NAT1, CYP2B6 | TDP1 3896/4885ERN1 3295/4885TRIM24 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.